Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$82.11-7.95%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · ZTS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 17.4% |
| Our one-year growth estimate | diamond | -1.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 12 industry peers · Company calendar date is not available
ZTS — dividend update
Dated 2026-10-08
Regulation FD Disclosure. On October 8, 2026, the Company declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on October 30, 2026. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…
Why it matters: Zoetis cut its 2026 revenue outlook sharply in August. Q3 results will show whether sales are tracking that lower range.
Watch forOn November 5, Q3 results keep full-year revenue guidance at $9.12 billion to $9.32 billion. Organic revenue is down 3% to 1%.
Also watch forZoetis cuts full-year revenue guidance below $9.12 billion or expects organic revenue to fall more than 3%.
Why it matters: U.S. companion animal sales fell 11% in both Q1 and Q2. A smaller decline would show demand is easing less.
Supportive ifQ3 U.S. companion animal sales decline by less than 11% year over year, or return to growth.
Worry ifQ3 U.S. companion animal sales fall 11% or more year over year again.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$119 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $315 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,706 loss on $10,000 · 47.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.